Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database

OBJECTIVE: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have significantly improved clinical effects on glycemic control. However, real-world data concerning the difference in gastrointestinal adverse events (AEs) among different GLP-1 RAs are still lacking. Our study aimed to characterize...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Lulu, Chen, Jia, Wang, Lei, Chen, Chen, Chen, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9770009/
https://www.ncbi.nlm.nih.gov/pubmed/36568085
http://dx.doi.org/10.3389/fendo.2022.1043789

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9770009/
https://www.ncbi.nlm.nih.gov/pubmed/36568085
http://dx.doi.org/10.3389/fendo.2022.1043789

Ejemplares similares